HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $51 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $51 price target.
June 26, 2023 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $51 price target.
The reiteration of a Buy rating and maintenance of a $51 price target by HC Wainwright & Co. analyst Raghuram Selvaraju indicates a positive outlook for Genmab's stock in the short term. This news is important for investors as it provides an expert opinion on the stock's potential performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100